Navigating CML Treatment: A Patient-Centered Approach - Episode 2
Interpreting Milestones: Prioritizing the Patient Picture
Panelists discuss how mutation analysis should be considered when treatment fails to meet milestones or patients show loss of response to tyrosine kinase inhibitor (TKI) therapy, as this information helps determine whether to continue the current TKI or switch to an alternative agent based on the specific resistance profile.
Video Player is loading.
Video content above is prompted by the following:
- If milestones are not reached, how do you determine whether to switch therapy or continue the current tyrosine kinase inhibitor?
- In what scenarios are you sending a BCR::ABL1 kinase domain mutation result for analysis?
Related Content:
